Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2023-04-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002453 |
| _version_ | 1797821360746004480 |
|---|---|
| author | Shiqi Mao Libo Luo Shuo Yang Yan Wang Fei Zhou Jia Yu Bin Chen Guanghui Gao Xuefei Li Chao Zhao Lei Cheng Yiwei Liu Wanying Wang Keyi Jia Chuchu Shao Xinyu Liu Xiaoxia Chen Chunxia Su Caicun Zhou Fengying Wu Shengxiang Ren Xiangxiang Pan Peifang Wei |
| author_facet | Shiqi Mao Libo Luo Shuo Yang Yan Wang Fei Zhou Jia Yu Bin Chen Guanghui Gao Xuefei Li Chao Zhao Lei Cheng Yiwei Liu Wanying Wang Keyi Jia Chuchu Shao Xinyu Liu Xiaoxia Chen Chunxia Su Caicun Zhou Fengying Wu Shengxiang Ren Xiangxiang Pan Peifang Wei |
| author_sort | Shiqi Mao |
| collection | DOAJ |
| first_indexed | 2024-03-13T09:52:30Z |
| format | Article |
| id | doaj.art-69faeb821edc43c4828978dc924eefa9 |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-03-13T09:52:30Z |
| publishDate | 2023-04-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-69faeb821edc43c4828978dc924eefa92023-05-24T07:29:24ZengWolters KluwerChinese Medical Journal0366-69992542-56412023-04-01136784885010.1097/CM9.0000000000002453202304050-00011Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutationShiqi MaoLibo LuoShuo YangYan WangFei ZhouJia YuBin ChenGuanghui GaoXuefei LiChao ZhaoLei ChengYiwei LiuWanying WangKeyi JiaChuchu ShaoXinyu LiuXiaoxia ChenChunxia SuCaicun ZhouFengying WuShengxiang RenXiangxiang PanPeifang Weihttp://journals.lww.com/10.1097/CM9.0000000000002453 |
| spellingShingle | Shiqi Mao Libo Luo Shuo Yang Yan Wang Fei Zhou Jia Yu Bin Chen Guanghui Gao Xuefei Li Chao Zhao Lei Cheng Yiwei Liu Wanying Wang Keyi Jia Chuchu Shao Xinyu Liu Xiaoxia Chen Chunxia Su Caicun Zhou Fengying Wu Shengxiang Ren Xiangxiang Pan Peifang Wei Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation Chinese Medical Journal |
| title | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_full | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_fullStr | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_full_unstemmed | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_short | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_sort | outcome comparison of pyrotinib with current standard of care in the second third line setting in advanced non small cell lung cancer patients with her2 mutation |
| url | http://journals.lww.com/10.1097/CM9.0000000000002453 |
| work_keys_str_mv | AT shiqimao outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT liboluo outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT shuoyang outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT yanwang outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT feizhou outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT jiayu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT binchen outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT guanghuigao outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT xuefeili outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chaozhao outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT leicheng outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT yiweiliu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT wanyingwang outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT keyijia outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chuchushao outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT xinyuliu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT xiaoxiachen outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chunxiasu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT caicunzhou outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT fengyingwu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT shengxiangren outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT xiangxiangpan outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT peifangwei outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation |